Garland J. Scott 4

What Happened
Garland J. Scott, a director of LB Pharmaceuticals Inc. (LBRX), was granted an award of 10,000 derivative shares on June 3, 2026. The reported acquisition price is $0.00, indicating a compensation-type grant (not an open-market purchase or sale). This was a grant/award transaction rather than a sale or market purchase.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Transaction type/code: A (Grant/Award/Other acquisition) of 10,000 derivative shares at $0.00.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnote: 100% of the shares underlying the award vest on the earlier of (i) June 3, 2027 or (ii) the date of the issuer’s next annual meeting of stockholders, subject to Scott’s continuous service through such vesting date.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in this filing.

Context
Grants to directors are commonly part of board compensation and vest over time; they are not the same as a market purchase (which some investors view as a stronger bullish signal). Because this is a derivative award with a service-based vesting schedule, it does not represent immediate share ownership or a sale and should be interpreted as compensation rather than a direct market investment. For full instrument details (RSU vs. option) check the complete Form 4 filing text.